Analysts show mixed responses to Modiv Industrial's latest performance. They've lowered revenue predictions and increased loss per share forecasts for next year. The company is anticipated to lag the industry, with revenues expected to shrink annually by 3.0% until 2024 end, against industry growth of 5.6%.
CEO Aaron Halfacre highlights strategy of offering monthly dividends, made possible by a robust dividend coverage ratio. Anticipation of receiving GIPR shares, to be distributed to Modiv's shareholders, exemplifies this approach.
Upgrades •$アルダ・メタル・パッケージング(AMBP.US)$: Barclays Upgrades to Overweight from Equalweight - PT $9 •$アメリカン・エキスプレス(AXP.US)$: Edward Jones Upgrades to Buy from Hold •$クラウドストライク(CRWD.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $215 (from $195) •$ルルレモン・アスレティカ(LULU.US)$: Bernstein Upgrades to Market Perform from Underperform - PT $300 (from $260) •$レスメド(RMD.US)$: RBC Upgrades to Outperform from Sector Perform - PT $244 (from $...
Gainers: •$クロビス・オンコロジー(CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$デア・バイオサイエンス(DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$クーラー・テクノロジー・グループ(KULR.US)$+9.5% (secured a battery sa...
モディブに関するコメント
コラムTop upgrades and downgrades on 6/6
• $アルダ・メタル・パッケージング(AMBP.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $9
• $アメリカン・エキスプレス(AXP.US)$ : Edward Jones Upgrades to Buy from Hold
• $クラウドストライク(CRWD.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $215 (from $195)
• $ルルレモン・アスレティカ(LULU.US)$ : Bernstein Upgrades to Market Perform from Underperform - PT $300 (from $260)
• $レスメド(RMD.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $244 (from $...
コラムToday's pre-market stock movers: CLVS, PATH, DARE and more
• $クロビス・オンコロジー(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $デア・バイオサイエンス(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $クーラー・テクノロジー・グループ(KULR.US)$ +9.5% (secured a battery sa...
まだコメントはありません